Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
09 Feb 2019
Historique:
received: 22 01 2019
revised: 06 02 2019
accepted: 06 02 2019
entrez: 13 2 2019
pubmed: 13 2 2019
medline: 30 5 2019
Statut: epublish

Résumé

We determined relationships of cholesterol efflux capacity (CEC), plasma cholesterol esterification (EST) and cholesteryl ester transfer (CET) with anti-c-terminus apoA-1 (Ac-terAA1) and anti-apolipoprotein (apo)-1 (AAA1) autoantibodies in subjects with and without Type 2 diabetes mellitus (T2D). In 75 T2D subjects and 75 nondiabetic subjects, Ac-terAA1 and AAA1 plasma levels were measured by enzyme-linked immunosorbent assay. CEC was measured as [³H]-cholesterol efflux from human cultured fibroblasts to diluted individual subject plasma. Plasma EST and CET were assayed by isotope methods. Ac-terAA1 and AAA1 levels and were similar between T2D and control subjects. Univariate regression analysis ( CEC, plasma EST and CET are inversely associated with Ac-terAA1 autoantibodies, conceivably attributable to an inverse relationship of these autoantibodies with apolipoprotein B-containing lipoproteins.

Sections du résumé

BACKGROUND BACKGROUND
We determined relationships of cholesterol efflux capacity (CEC), plasma cholesterol esterification (EST) and cholesteryl ester transfer (CET) with anti-c-terminus apoA-1 (Ac-terAA1) and anti-apolipoprotein (apo)-1 (AAA1) autoantibodies in subjects with and without Type 2 diabetes mellitus (T2D).
METHODS METHODS
In 75 T2D subjects and 75 nondiabetic subjects, Ac-terAA1 and AAA1 plasma levels were measured by enzyme-linked immunosorbent assay. CEC was measured as [³H]-cholesterol efflux from human cultured fibroblasts to diluted individual subject plasma. Plasma EST and CET were assayed by isotope methods.
RESULTS RESULTS
Ac-terAA1 and AAA1 levels and were similar between T2D and control subjects. Univariate regression analysis (
CONCLUSIONS CONCLUSIONS
CEC, plasma EST and CET are inversely associated with Ac-terAA1 autoantibodies, conceivably attributable to an inverse relationship of these autoantibodies with apolipoprotein B-containing lipoproteins.

Identifiants

pubmed: 30744100
pii: ijms20030732
doi: 10.3390/ijms20030732
pmc: PMC6387386
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Apolipoprotein A-I 0
Biomarkers 0
Cholesterol, HDL 0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest

Références

J Lipid Res. 1999 Aug;40(8):1467-74
pubmed: 10428983
Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1082-8
pubmed: 10764677
Atherosclerosis. 2001 Jul;157(1):49-56
pubmed: 11427203
J Biol Chem. 2003 Dec 26;278(52):52379-85
pubmed: 14559902
Eur J Clin Invest. 2003 Dec;33(12):1051-69
pubmed: 14636288
Diabetologia. 2005 Jun;48(6):1105-13
pubmed: 15875154
Diabetes. 2005 Dec;54(12):3554-9
pubmed: 16306375
Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):541-7
pubmed: 16410457
J Biol Chem. 2006 Dec 1;281(48):37081-90
pubmed: 17020879
Atherosclerosis. 2008 Feb;196(2):733-41
pubmed: 17275009
Curr Opin Lipidol. 2007 Jun;18(3):251-7
pubmed: 17495597
Diabetologia. 2007 Aug;50(8):1770-9
pubmed: 17579831
Atherosclerosis. 1991 Oct;90(2-3):159-68
pubmed: 1759986
Clin Sci (Lond). 2008 Jul;115(1):25-33
pubmed: 18088236
Eur J Endocrinol. 2008 Jan;158(1):53-60
pubmed: 18166817
Biochim Biophys Acta. 2008 Jan-Feb;1781(1-2):10-5
pubmed: 18178167
Diabetes. 1991 Mar;40(3):377-84
pubmed: 1847886
Rheumatology (Oxford). 2009 Jan;48(1):26-31
pubmed: 19000993
Atherosclerosis. 2010 Feb;208(2):537-42
pubmed: 19698944
Diabetes. 2009 Dec;58(12):2711-7
pubmed: 19940234
Lupus. 2010 May;19(6):711-6
pubmed: 20064910
Eur Heart J. 2010 Apr;31(7):815-23
pubmed: 20176799
Arthritis Rheum. 2010 Sep;62(9):2640-50
pubmed: 20506304
Arthritis Rheum. 2011 Jan;63(1):201-11
pubmed: 20882670
Eur Heart J. 2011 Feb;32(4):412-21
pubmed: 21224292
N Engl J Med. 2011 Apr 14;364(15):1473-4; author reply 1474-5
pubmed: 21488781
Atherosclerosis. 2011 Jul;217(1):249-52
pubmed: 21524747
J Intern Med. 2012 Oct;272(4):344-57
pubmed: 22329401
Arterioscler Thromb Vasc Biol. 2013 May;33(5):1098-104
pubmed: 23430610
Biomark Med. 2013 Jun;7(3):457-72
pubmed: 23734809
J Lipid Res. 2014 Feb;55(2):168-79
pubmed: 23812558
Eur J Clin Invest. 2014;44(3):240-8
pubmed: 24325778
Atherosclerosis. 2014 May;234(1):185-92
pubmed: 24661908
World J Cardiol. 2014 May 26;6(5):314-26
pubmed: 24944761
J Biol Chem. 2014 Aug 29;289(35):24020-9
pubmed: 25074931
J Biol Chem. 2014 Oct 10;289(41):28249-59
pubmed: 25170076
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
Eur J Clin Invest. 2015 Apr;45(4):369-79
pubmed: 25627775
Thromb Haemost. 2015 Aug;114(2):410-22
pubmed: 25879306
Lancet Diabetes Endocrinol. 2015 Jul;3(7):507-13
pubmed: 26025389
PLoS One. 2015 Jul 15;10(7):e0132780
pubmed: 26177543
J Diabetes Complications. 2016 May-Jun;30(4):580-5
pubmed: 26965796
Sci Rep. 2016 Jun 08;6:27367
pubmed: 27270665
Endocrinol Metab (Seoul). 2016 Jun;31(2):223-9
pubmed: 27302716
Thromb Haemost. 2016 Sep 27;116(4):764-71
pubmed: 27384400
Eur J Clin Invest. 2016 Sep;46(9):805-17
pubmed: 27490973
Front Immunol. 2017 Apr 18;8:437
pubmed: 28458671
Nat Rev Cardiol. 2018 Jan;15(1):9-19
pubmed: 28795686
Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2342-2349
pubmed: 29074586
Thromb Haemost. 2018 Jun;118(6):1088-1100
pubmed: 29723873
Scand J Clin Lab Invest. 1987 Oct;47(6):613-7
pubmed: 3672034
J Biol Chem. 1981 Mar 10;256(5):2102-4
pubmed: 7462232
Atherosclerosis. 1998 Apr;137 Suppl:S13-7
pubmed: 9694536
Atherosclerosis. 1998 Sep;140(1):71-9
pubmed: 9733217

Auteurs

Robin P F Dullaart (RPF)

Department of Endocrinology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands. r.p.f.dullaart@umcg.nl.

Sabrina Pagano (S)

Division of Laboratory Medicine, Department of Diagnostics, Hộpitaux Universitaires de Geneve, 1211 Geneva, Switzerland. Sabrina.Pagano@hcuge.ch.
Department of Internal Medicine Specialities, Medical Faculty, Hộpitaux Universitaires de Geneve, 1211 Geneva, Switzerland. Sabrina.Pagano@hcuge.ch.

Frank G Perton (FG)

Department of Endocrinology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, the Netherlands. f.g.perton@umcg.nl.

Nicolas Vuilleumier (N)

Division of Laboratory Medicine, Department of Diagnostics, Hộpitaux Universitaires de Geneve, 1211 Geneva, Switzerland. Nicolas.Vuilleumier@hchuge.nl.
Department of Internal Medicine Specialities, Medical Faculty, Hộpitaux Universitaires de Geneve, 1211 Geneva, Switzerland. Nicolas.Vuilleumier@hchuge.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH